|Bid||41.71 x 800|
|Ask||41.74 x 1400|
|Day's Range||41.67 - 42.06|
|52 Week Range||32.22 - 42.76|
|Beta (3Y Monthly)||0.30|
|PE Ratio (TTM)||27.56|
|Forward Dividend & Yield||0.72 (1.84%)|
|1y Target Est||N/A|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Emerging markets, especially China, have been a bright spot for the company as its mature markets, including the United States which accounts for about half of its revenue, stabilise after a shaky start to last year. Growth of 15.3 percent in emerging markets powered Smith & Nephew's total revenue to $1.20 billion (£919.4 million), in line with analysts' expectations, according to a company-compiled consensus http://www.smith-nephew.com/investor-centre/reporting/analyst-consensus. Demand from emerging markets will continue to lift the company as patient populations grow and medical expertise improves, Chief Executive Officer Namal Nawana told Reuters.
Attractive stocks have exceptional fundamentals. In the case of Smith & Nephew plc (LON:SN.), there's is a notable dividend-paying company that has been able to sustain great financial health over t...
New offices for Wabtec, Smith & Nephew and SAP helped stoke new office develop in the city's urban fringe
Today we'll look at Smith & Nephew plc (LON:SN.) and reflect on its potential as an investment. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. F...
London firm to take new space as first tenant at Stacks at 3 Crossings for the one-time Carnegie Mellon University robotic surgery spin off it bought for $275 million.
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The fourth quarter of 2018 is one of those periods, as the Russell […]
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are currently a shareholder in Smith & Nephew plc (LON:SN.), or considering investing in the stock, you need to examin...
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. ForRead More...
The deal will help Smith & Nephew better compete with bigger rivals such as U.S.-based Johnson & Johnson as Osiris's products, including skin and bone grafts, complements its portfolio of wound care products. "Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business," Smith & Nephew Chief Executive Officer Namal Nawana said.
Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as the British medical products maker looks to bulk up in an area that is quickly growing. The deal will help Smith & Nephew better compete with bigger rivals such as U.S.-based Johnson & Johnson as Osiris's products, including skin and bone grafts, complements its portfolio of wound care products. "Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business," Smith & Nephew Chief Executive Officer Namal Nawana said.
British medical products maker Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as it looks to boost profit margins and find ...
First reported by the Financial Times late Friday, NuVasive shares jumped as much as 18% on the Nasdaq Stock Exchange in after-hours trading. Citing "people with direct knowledge of the talks," the Financial Times noted that discussions between the companies were ongoing and that no definitive deal had been reached. London-based Smith & Nephew produces a wide range of medical equipment and products, including "advanced wound management products" and orthopedic reconstruction devices.
NuVasive stock popped Monday on a report Smith & Nephew could be considering buying it for about $3 billion. NuVasive stock made double-digit percentage gains in high volume on the news.
NuVasive stock was on the rise Monday following news of a potential takeover from Smith & Nephew (NYSE:SNN).Source: Shutterstock The recent NuVasive (NASDAQ:NUVA) news claims that Smith & Nephew is looking to pick the company up for a price of $3 billion. This information comes from unnamed sources that are reportedly close to the takeover talks.According to these anonymous sources, the talks between NuVasive and Smith & Nephew are still ongoing and there still isn't a final agreement for the companies. As such, it is possible that the deal may not go on to reach completion, reports TheStreet.com.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNuVasive is the developer of treatments for chronic back pain and other issues with the spine. It fixes these problems with a type of minimally invasive surgery called Maximum Access Surgery. This only requires a small incision, about one inch to two inches, on the back.Smith & Nephew is a multinational l medical equipment manufacturing company. It headquarters is based out of London. The company has been around since 1856 and trades on the New York Stock Exchange, as well as the London Stock Exchange. * 10 Best Dividend Stocks to Buy for the Next 10 Months News about a possible takeover of NUVA really sent NuVasive stock soaring on Monday. The stock was up 15% as of Monday morning. However, this same news saw SNN stock dropping today. Smith & Nephew stock was down 4% as of noon Monday, but it is still up 10% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Fundamentally Sound Dividend Stocks to Buy * 5 Reasons Reeling FAANG Stocks Won't Deliver Big Returns * 3 Reasons Canopy Growth Could Burn You As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post NuVasive Stock Shoots Higher on Takeover Talk appeared first on InvestorPlace.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Smith & Nephew plc (LON:SN.), a large-capRead More...
When contacted by Reuters, Smith & Nephew and NuVasive said they do not comment on market speculation. The exact terms of any talks could not be learned, and the discussions may still fall apart, the FT reported. The acquisition would mark the first major move by Smith & Nephew Chief Executive Namal Nawana.